Harpoon Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in South San Francisco, California and currently employs 53 full-time employees. The company went IPO on 2019-02-08. Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company. The firm is engaged in the developing a T cell engager that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. The firm is developing a pipeline of T cell engagers using its TriTACs technology, focused on the treatment of solid tumors and hematologic malignancies. The company has also nominated its clinical candidate using its ProTriTAC platform, a prodrug version of its TriTAC platform, designed to expand the target space for T cell engagers and bring the benefits of TriTACs to the patients. The Company’s TriTAC product candidates include HPN217, and HPN328. The Company’s ProTriTAC product candidate include HPN601, which is being developed for the treatment of multiple solid tumor indications.

Industry: Biological Products, (No Diagnostic Substances) Peers: AIM ImmunoTech Inc Ainos Inc Jasper Therapeutics Inc Oruka Therapeutics Inc Codiak BioSciences, Inc. Crescent Biopharma Inc Pasithea Therapeutics Corp Vicapsys Life Sciences, Inc.